Initial Public Offering. A biotechnology company, Keros Therapeutics, completed its IPO on April 8, 2020, and listed on the Nasdaq. Keros sold 6,000,000 shares of stock to primary market investors at an IPO offer price of $15.64, with an underwriting discount of 6.6%. Secondary market investors, however, were paying $20.57 per share for Keros' 19,189,391 shares of stock outstanding (which includes the newly-issued shares). a. Calculate the total proceeds for Keros' IPO. b. Calculate the dollar amount of the underwriting fee for Keros' IPO. c. Calculate the net proceeds for Keros' IPO. d. Calculate market capitalization for Keros' outstanding stock. e. Calculate IPO underpricing for Keros' IPO. f. Explain the IPO underpricing for Keros. a. The total proceeds for Keros' IPO is S (Round to the nearest dollar.) b. The dollar amount of the underwriting fee for Keros' IPO is $[. (Round to the nearest dollar.) c. The net proceeds for Keros' IPO is $(). (Round to the nearest dollar.) d. Keros' market capitalization is $ (Round to the nearest dollar.) e. Keros' IPO underpricing is %. (Round to two decimal places.) f. Explain the IPO underpricing for Keros. "Positive underpricing indicates that secondary-market investors were willing to pay more for the company's shares than the IPO offer price that the shares were sold for in the primary market." This statement is (Select the best answer from the drop-down menu.)